PMID- 23103659
OWN - NLM
STAT- MEDLINE
DCOM- 20130726
LR  - 20211001
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
VI  - 34
IP  - 6
DP  - 2013 Feb
TI  - Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide 
      nanoparticles: a human study using a multi-parametric cardiovascular magnetic 
      resonance imaging approach.
PG  - 462-75
LID - 10.1093/eurheartj/ehs366 [doi]
AB  - AIMS: The purpose of this clinical trial was to investigate whether 
      cardiovascular magnetic resonance imaging (CMR) using ferumoxytol (Feraheme, 
      FH), an ultrasmall superparamagnetic iron oxide nanoparticle (USPIO), allows more 
      detailed characterization of infarct pathology compared with conventional 
      gadolinium-based necrosis/fibrosis imaging in patients with acute myocardial 
      infarction. METHODS AND RESULTS: Fourteen patients who had experienced an acute 
      ST-elevation myocardial infarction were included in this study. Following 
      coronary angiography, a first baseline study (pre-FH) was performed followed by 
      subsequent CMR studies (post-FH) 48 h after intravenous ferumoxytol 
      administration. The CMR studies comprised cine-CMR, T(2)-weighted short tau 
      inversion recovery spin echo imaging, T(2)-mapping, and T(1)-weighted late 
      gadolinium enhancement (LGE) imaging. The median extent of short-axis in-plane 
      LGE was 30% [inter-quartile range (IQR) 26-40%]. The median in-plane extent of 
      T(2)-weighted 'hypoenhancement' in the region of myocardial infarction, which was 
      not present prior to ferumoxytol administration in any patient, was 19% (IQR 
      14-22%; P < 0.001 compared with the extent of LGE). The median in-plane extent of 
      areas showing signal void in T(2)-mapping images post-FH in the region of 
      myocardial infarction was 16% (IQR 12-18%; P < 0.001 compared with the extent of 
      LGE; P = 0.34 compared with the extent of T(2)-weighted hypoenhancement). A 
      substantial drop in absolute T(2)-values was observed not only in the infarct 
      core and peri-infarct zone, but also in the remote 'healthy' myocardium, although 
      there was only a minor change in the skeletal muscle. Substantial ferumoxytol 
      uptake was detected only in cultured macrophages, but not in peripheral blood 
      monocytes from study patients. CONCLUSION: We could demonstrate in humans that 
      USPIO-based contrast agents enable a more detailed characterization of myocardial 
      infarct pathology mainly by detecting infiltrating macrophages. Considering the 
      multi-functionality of USPIO-based particles and their superior safety profile 
      compared with gadolinium-based compounds, these observations open up new vistas 
      for the clinical application of USPIO.
FAU - Yilmaz, Ali
AU  - Yilmaz A
AD  - Division of Cardiology, Robert-Bosch-Krankenhaus, Stuttgart, Germany. 
      ali.yilmaz@rbk.de
FAU - Dengler, Michael A
AU  - Dengler MA
FAU - van der Kuip, Heiko
AU  - van der Kuip H
FAU - Yildiz, Handan
AU  - Yildiz H
FAU - Rosch, Sabine
AU  - Rosch S
FAU - Klumpp, Siegfried
AU  - Klumpp S
FAU - Klingel, Karin
AU  - Klingel K
FAU - Kandolf, Reinhard
AU  - Kandolf R
FAU - Helluy, Xavier
AU  - Helluy X
FAU - Hiller, Karl-Heinz
AU  - Hiller KH
FAU - Jakob, Peter M
AU  - Jakob PM
FAU - Sechtem, Udo
AU  - Sechtem U
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121026
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Contrast Media)
RN  - 0 (Dextrans)
RN  - 0 (Magnetite Nanoparticles)
RN  - 0 (ferumoxtran-10)
RN  - XM0M87F357 (Ferrosoferric Oxide)
SB  - IM
MH  - Cells, Cultured
MH  - *Contrast Media/pharmacokinetics
MH  - *Dextrans/pharmacokinetics
MH  - Ferrosoferric Oxide/pharmacokinetics
MH  - Humans
MH  - Leukocytes, Mononuclear/metabolism
MH  - Magnetic Resonance Angiography/methods
MH  - *Magnetite Nanoparticles
MH  - Middle Aged
MH  - Myocardial Infarction/*diagnosis
MH  - Prospective Studies
MH  - Time Factors
EDAT- 2012/10/30 06:00
MHDA- 2013/07/28 06:00
CRDT- 2012/10/30 06:00
PHST- 2012/10/30 06:00 [entrez]
PHST- 2012/10/30 06:00 [pubmed]
PHST- 2013/07/28 06:00 [medline]
AID - ehs366 [pii]
AID - 10.1093/eurheartj/ehs366 [doi]
PST - ppublish
SO  - Eur Heart J. 2013 Feb;34(6):462-75. doi: 10.1093/eurheartj/ehs366. Epub 2012 Oct 
      26.